Roche’s Lunsumio VELO Gains FDA Accelerated Approval for Lymphoma Treatment
A New Horizon in Lymphoma Treatment: Roche’s Lunsumio VELO Gains FDA Accelerated Approval The landscape of cancer therapy has advanced with the United States Food and Drug Administration (FDA) granting accelerated approval to Lunsumio VELO. Developed by Roche, known as glofitamab, this treatment marks a pivotal moment for patients battling aggressive lymphoma, offering a much-needed…
